Ucb Pharma, S.a.

Ucb Biopharma Sprl

Ucbbiopharma Srl

Celltech R&d Limited

Celltech Therapeutics Limited

Sanofi

Alastair David Griffiths Lawson

Terence Seward Baker

Helene Margaret Finney

Kerry Louise Tyson

Ralph Adams

Andrew George Popplewell

Daniel John Lightwood

Bryan John Smith

Stevan Graham Shaw

Marc Roger De Ryck

Karen Margrete Miller

Christian Gilbert J Wolff

Yi Lin Zhang

Lara Kevorkian

Andrew Malcolm Nesbitt

Neil Gozzard

Derek Thomas Brown

John Robert Porter

David Paul Humphreys

Sam Philip Heywood

Kaushik Sarkar

Paul Alan Atherfold

Meryn Ruth Griffiths

Christoph Meier

Diana Shpektor

Roger Thomas Palframan

James Philip O'Connell

Alistair James Henry

Xiaofeng Liu

Rebecca Jayne Munro

Paul Edward Stephens

James Heads

Karen Dorothy Cromie

Sebastian Kelm

Jiye Shi

Hishani Kirby

Lisa Butler

Yi Zhang

Stephen Graham Shaw

Terry Seward Baker

The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

Anti-FcRn antibodies

The present invention provides a method for generation of multi-domain proteins, more particular antibodies, with an improved native state colloidal stability. The present disclosure provides a method of producing an IgG1 or IgG4 antibody with an improved colloidal stability comprising, in embodiments: calculating for each domain of said IgG1 or IgG4 antibody the total net charge at a given pH; introducing one or more modifications to the amino acid residues of the constant region of said IgG1 or IgG4 antibody to minimize the charge sign difference between the domains, wherein said one or more modification is, or each are, a substitution of a charged amino acid by a polar (non-charged) amino acid; and producing the modified multi-domain protein with improved colloidal stability at the given pH.

Multi-domain proteins with increased native state colloidal stability

Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-molecular or inter-molecular atom to atom contacts extracted from a database of biological macromolecules to identify favoured regions adjacent to the binding site for particular atom types and modifying a candidate ligand to increase the intersection between atoms of the candidate ligand and the favoured regions. One or more steps of the methods may be performed by a computer.

Obtaining an improved therapeutic ligand

The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Expression vector encoding antibody molecule which binds IL-17A and IL-17F

It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.

Antibody against trimeric TNF&#x3b1; complex

The present invention relates to single chain polypeptides comprising one or more immunoglobulin Fc domains. In particular the present invention relates to single-chain Fc polypeptides in which at least one functional Fc domain is formed within the polypeptide chain.

Single chain FC polypeptides

A Na1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Na1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

[object Object]

The present invention relates to an improved method for drug discovery. In particular the present invention provides a method of identifying compounds capable of binding to a functional conformational state of a protein of interest or protein fragment thereof, said method comprising the steps of: (a) Binding a function-modifying antibody to the target protein of interest or a fragment thereof to provide an antibody-constrained protein or fragment, wherein the antibody has binding kinetics with the protein or fragment which are such that it has a low dissociation rate constant, (b) Providing a test compound which has a low molecular weight, (c) Evaluating whether the test compound of step b) binds the antibody constrained protein or fragment, and (d) Select a compound from step c) based on the ability to bind to the protein or fragment thereof.

Method for identifying compounds of therapeutic interest

The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Antibody molecules having specificity for human OX40

Methods of treatment using antibodies which bind IL-17A and IL-17F

The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing antibody molecules.

Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13

The present invention provides anti-TNF&#x3b1; antibodies which selectively inhibit TNF&#x3b1; signalling through the p55R. In particular the present invention provides anti-TNF&#x3b1; antibodies which selectively inhibit TNF&#x3b1; signalling through the p55R relative to the p75R.

Anti-TNF alpha antibodies which selectively inhibit TNF alpha signalling through the p55R

An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Method of treating a patient for pain by administering an anti-ion channel antibody

Growing community of inventors

Slough, United Kingdom

Alastair David Griffiths Lawson